Actively Recruiting
To Evaluate KC1036 in the Patients with Advanced Digestive System Tumors
Led by Beijing Konruns Pharmaceutical Co., Ltd. · Updated on 2024-10-17
133
Participants Needed
13
Research Sites
205 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate the preliminary efficacy, safety, tolerability and pharmacokinetics of KC1036 in participants with advanced recurrent or metastatic digestive system tumors.
CONDITIONS
Official Title
To Evaluate KC1036 in the Patients with Advanced Digestive System Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically or cytologically confirmed malignant digestive system tumors
- Advanced recurrent, unresectable and/or metastatic digestive system tumors with prior failure of standard treatments
- Eastern Cooperative Oncology Group performance status score of 0 or 1
- Life expectancy greater than 12 weeks
- Body mass index (BMI) of 18.0 or higher
- Adequate hematologic, renal, and hepatic function
- Voluntary participation with signed informed consent
You will not qualify if you...
- Known central nervous system metastasis with symptoms
- Presence of other types of malignancies
- Gastrointestinal abnormalities
- Cardiovascular and cerebrovascular diseases
- Previous treatment with small molecule vascular targeting inhibitors
- Anti-tumor therapies (chemotherapy, radiotherapy, hormonotherapy, biotherapy, immunotherapy, surgery) within 4 weeks before enrollment
- Participation in other clinical trials within 4 weeks before enrollment
- Major surgery, open biopsy, or significant injury within 4 weeks before enrollment
- Uncontrolled massive ascites, pleural or pericardial effusion
- Active bacterial, viral, or fungal infections or fever over 38.5°C within 2 weeks before enrollment
- Known HIV infection or chronic/active hepatitis B or C infection
- Pregnant or lactating women or those not using contraceptives, including men
- Other metabolic dysfunctions, abnormal physical exams, or lab findings
- Inability to comply with required study procedures
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 13 locations
1
Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, China, 100021
Actively Recruiting
2
The first affiliated hospital of bengbu medical college
Bengbu, China
Actively Recruiting
3
Chongqing University Three Gorges Hospital
Chongqing, China
Actively Recruiting
4
Fujian Cancer Hospital
Fujian, China
Actively Recruiting
5
Henan Cancer Hospital Affiliated Cancer Hospital of Zhengzhou University
Henan, China
Actively Recruiting
6
The First Affiliated Hospital of Xinxiang Medical University
Henan, China
Actively Recruiting
7
Hubei Cancer Hospital
Hubei, China
Actively Recruiting
8
Union Hospital Tongji Medical College Huazhong University of Science and Technologe
Hubei, China
Actively Recruiting
9
Shandong Cancer Hospital & Institute
Shandong, China
Actively Recruiting
10
Shanghai Chest Hospital
Shanghai, China
Actively Recruiting
11
Cancer Hospital Chinese Academy of Medical Sciences,Shenzhen Center
Shenzhen, China
Actively Recruiting
12
Tianjin Medical University Cancer Institute &Hospital
Tianjin, China
Actively Recruiting
13
The Second Affiliated Hospital Zhejiang University School of Medicine
Zhejiang, China
Actively Recruiting
Research Team
J
Jing Huang, Medicine Doctor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here